首页> 外文期刊>Clinical and experimental allergy : >A critical assessment of allergen component-based in vitro diagnosis in cherry allergy across Europe.
【24h】

A critical assessment of allergen component-based in vitro diagnosis in cherry allergy across Europe.

机译:整个欧洲对樱桃过敏的基于过敏原成分的体外诊断的重要评估。

获取原文
获取原文并翻译 | 示例
           

摘要

Background Food allergy to cherry occurs throughout Europe, typically with restricted oral reactions in the central and northern parts but with frequent systemic reactions in the Mediterranean region. Previous studies have demonstrated insufficient sensitivity of commercially available cherry extract reagents in the diagnosis of cherry allergy. Objective To assess the diagnostic performance of specific IgE tests based on recombinant cherry allergens in comparison with an extract-based assay and to skin prick test (SPT). A secondary objective was to analyse the frequency of systemic reactions in cherry-allergic subjects across Europe, including the largest population of LTP-sensitized subjects from central Europe studied to date. Methods A total of 186 subjects from central Europe and Spain were studied. Serum IgE was analysed with ImmunoCAP tests carrying rPru av 1, 3 and 4, combined and separately, and cherry extract. Results Among the central European cherry allergics, the mix of rPru av 1, 3 and 4 had a sensitivity of 95%, compared with 65% for cherry extract, and the IgE binding capacity of the recombinant mix was considerably higher. The sensitivity of the two tests was more comparable in the Spanish population, 95% and 86%, respectively. The recombinant allergen ImmunoCAP equalled SPT in terms of sensitivity and specificity. Consistent with previous reports, major geographic differences in sensitization pattern and prevalence of systemic reactions were found. A significantly higher rate of systemic reactions was found in Spanish patients sensitized to Pru av 3 whereas German patients sensitized to LTP only had oral allergy syndrome. Conclusions The recombinant cherry allergen ImmunoCAP is a highly sensitive diagnostic tool, clearly superior to any diagnostic method based on cherry extract. Three cherry allergens are sufficient for detecting sensitization in 95% of cherry-allergic subjects. Systemic reactions are common in LTP-sensitized individuals but seem to require at least one additional causative factor.
机译:背景技术对樱桃的食物过敏发生在整个欧洲,通常在中部和北部发生口腔反应受限,而在地中海地区则发生频繁的全身性反应。先前的研究表明,市售的樱桃提取物试剂在诊断樱桃过敏中的敏感性不足。目的与基于提取物的检测和皮肤点刺试验(SPT)相比,评估基于重组樱桃过敏原的特定IgE试验的诊断性能。第二个目标是分析整个欧洲对樱桃过敏性受试者的全身反应的频率,其中包括迄今为止研究的来自中欧的对LTP敏感的受试者的最大群体。方法对来自中欧和西班牙的186名受试者进行了研究。血清IgE用携带rPru av 1、3和4合并单独使用的樱桃提取物的ImmunoCAP测试进行分析。结果在中欧樱桃过敏症中,rPru av 1、3和4的混合物对樱桃提取物的敏感性为95%,而对樱桃提取物的敏感性为65%,重组混合物的IgE结合能力更高。两项测试的敏感性在西班牙人群中更具可比性,分别为95%和86%。就敏感性和特异性而言,重组变应原ImmunoCAP等于SPT。与以前的报告一致,在致敏模式和全身反应的普遍性方面发现了主要的地理差异。在对Pru av 3致敏的西班牙患者中发现全身性反应的比率明显更高,而对LTP致敏的德国患者仅具有口腔过敏综合症。结论重组樱桃过敏原ImmunoCAP是一种高度敏感的诊断工具,明显优于任何基于樱桃提取物的诊断方法。三种樱桃过敏原足以检测95%的樱桃过敏受试者的致敏性。系统性反应在LTP致敏的个体中很常见,但似乎至少需要另外一种致病因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号